Highlights

CCO Independent Conference Coverage: Clinical Impact of New HIV Data From Fall 2022 Conferences*

Washington, DC - October 19-23, 2022; Glasgow, Scotland and virtual - October 23-26, 2022

Engage in this scientific analysis of data presented at IDWeek and HIV Glasgow 2022, with rapid postconference webinars by expert faculty and Capsule Summaries on key HIV prevention and treatment studies and new and investigational ART regimens. Watch the on-demand webinars, download the slides, and gain global perspectives with companion ClinicalThought commentaries.

BANNER Study: Broadly Neutralizing Antibody VH3810109 in People With HIV Naive to Treatment

ATLAS, ATLAS-2M, and FLAIR Pooled Analysis: Factors Associated With Virologic Failure in PWH Receiving LA CAB + RPV Using Expanded Multivariable Models

Selection of Optimal Islatravir Doses for Persons With HIV Naive to Treatment and Switching From Stable Therapy Through Modeling and Simulation

Real-world Effectiveness of Long-Acting CAB + RPV in the First Yr in the US OPERA Cohort

CARISEL: Clinical Outcomes by Implementation Strategy of Patients Receiving LA CAB + RPV in European Healthcare Settings

CAPELLA: Wk 52 Results With Long-Acting SC Lenacapavir in Randomized and Nonrandomized Cohorts of Persons With Multidrug-Resistant HIV

Survey of PrEP Interest, Usage, and Awareness Among US Cisgender Women

Protocol 011: Post Hoc Analysis of Lymphocyte Changes in PWH Receiving Islatravir

HPTN 083: HIV Infections in the Yr 1 Unblinded Period in MSM and TGW Receiving Injectable CAB for HIV PrEP

BICSTaR: BIC/FTC/TAF Effectiveness and Safety by Demographics and Baseline Characteristics at 24 Mo

CCO Independent Conference Coverage: Clinical Impact of New HIV Data From Fall 2022 Conferences*

10 Capsule Summary Slidesets

Leaving the CCO site